191 - One Size Fits One: Toward Individualized Management of Infectious Diseases

Wednesday, October 22, 2025

8:00 AM - 9:00 AM US ET

Location: B308-B309

CME Credits: Maximum of 1 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1 hours of MOC Credit
CNE Credits: Maximum of 1 hours of ANCC Credit
ACPE Credits: ACPE 1 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

Luther Bartelt, MD

Associate Professor, Infectious Diseases
University of North Carolina School of Medicine
Chapel Hill, NC, United States
Mahalia Desruisseaux, MD (she/her/hers)

Associate Professor
Yale School of Medicine
New Haven, CT, United States

Faculty(s)

Anne Friedland, MD (she/her/hers)

Assistant Professor
UNC School of Medicine
Chapel Hill, NC, United States
Graham Hatfull, PhD (he/him/his)

Professor
University of Pittsburgh
Pittsburgh, PA, United States
Vance Fowler, MD, MHS

Professor of Medicine
Division of Infectious Diseases
Duke University Medical Center
Durham, NC, United States

Disclosure(s):

Luther A. Bartelt, MD: No financial relationships to disclose.

Mahalia S. Desruisseaux, MD: No financial relationships to disclose.

Anne Friedland, MD: Paratek Pharmaceuticals: Grant/Research Support

Graham Hatfull, PhD: ePhective: Advisor/Consultant, Stocks/Bonds (Private Company)

Vance G. Fowler, MD, MHS: Akagera: Advisor/Consultant; Armata: Advisor/Consultant; AstraZeneca: Advisor/Consultant, Grant/Research Support; Basilea: Advisor/Consultant, Grant/Research Support; Contrafect: Grant/Research Support; Debiopharm: Advisor/Consultant; EDE: Grant/Research Support; GSK: Advisor/Consultant; Integrated Biotherapeutics: Advisor/Consultant; Jansenn: Grant/Research Support; Merck: Grant/Research Support; Up to Date: Honoraria

Learning Objectives:

At the conclusion of this session, participants will be able to:

describe ongoing research into ways to optimize treatment duration at the individual patient level;
identify the role of molecular and biomarker data for informing treatment duration;
explain the range of referral tools available for ancillary testing for investigational therapies for difficult to treat organisms.

Presentations:

8:00 AM - 8:20 AM US ET

Molecular Diagnostics to Refine Duration of Therapy for Blood Stream Infection: S. aureus
Speaker: Vance G. Fowler, MD, MHS – Duke University Medical Center
8:20 AM - 8:40 AM US ET

Laboratory-Guided Isolate-Specific Treatment Modifications: Mycobacterium abscessus (Clinical)
Speaker: Anne Friedland, MD (she/her/hers) – UNC School of Medicine
8:40 AM - 9:00 AM US ET

Laboratory-Guided Isolate-Specific Treatment Modifications: Mycobacterium abscessus (Laboratory)
Speaker: Graham Hatfull, PhD (he/him/his) – University of Pittsburgh